a team of researchers from South Korea conducted a randomized, placebo-controlled, double-blind clinical trial to determine whether children receiving intensive physical therapy, umbilical cord stem cell transplantation, and the hormone erythropoietin (which is used to stimulate stem cell growth) resulted in higher cognitive and physical functioning scores than children who received only erythropoietin and physical therapy or those that only underwent intensive physical therapy.
Table 1
Sources: National Institutes of Health Clinical Trials Registry (2014). Clinical trials registry. Retrieved from http://clinicaltrials.gov and Cerebral Palsy International Research Foundation (2014). New research FY 2014. Retrieved from http://cpirf.org/research/active-projects.
The transplantation of cord blood stem cells is currently available in other countries as a treatment modality for CP despite opposition from the scientific community. Because the science of cord blood transplantation is a relatively new science with emerging results in human clinical trials, multiple CP organizations have formally advised against the procedure until safety of the treatment can be verified through the scientific process. Researchers agree that stem cell transplantation, particularly through allogeneic or sibling cord blood, seems to hold the greatest hope for a partial cure or improvement of functioning.
While advances in science create excitement for future treatment modalities, it should be weighed that stem cell therapy is not without risks. Side effects from stem cell therapy transplantations have included recipient-to-host graft disease, including encephalopathy due to infection, organ failure, medication reaction, seizures, acute disseminated encephalomyelitis, thrombotic thrombocytopenic purpura, or stroke. Although adult stem cell transplants have reportedly been performed in large numbers for individuals with CP outside the United States with no reported adverse outcomes, the lack of quality clinical trials and published research does not support advocating these interventions.
Michele Davidson
George Mason University
See Also: Adult Stem Cells: Overview; Cord Blood Stem Cells.
Further Readings
Carroll, J. E. and R. W. Mays. “Update on Stem Cell Therapy for Cerebral Palsy.” Expert Opinion on Biological Therapies, v.11/4 (2011).
Centers for Disease Control and Prevention. “Data and Statistics for Cerebral Palsy” (2014). http://www.cdc.gov/ncbddd/cp/data.html (Accessed April 2014).
Cerebral Palsy International Research Foundation. “New Research FY 2014.” http://cpirf.org/research/active-projects (Accessed April 2014).
Morris, C. and D. Condie. Recent Developments in Healthcare for Cerebral Palsy: Implications and Opportunities for Orthotics. Brussels: International Society for Prosthetics and Orthotics, 2008.
National Institutes of Health, Clinical Trials Registry. “Clinical Trials Registry.” http://clinicaltrials.gov (Accessed April 2014).
Clinical Trials Outside the United States: Spinal Cord Injury
Clinical Trials Outside the United States: Spinal Cord Injury
291
293
Clinical Trials Outside the United States: Spinal Cord Injury
Spinal cord injury (SCI) is a devastating condition that causes significant morbidity and mortality. Spinal cord injury can occur anywhere between the neck and the lower back. SCI mostly affects young adults, and motor vehicle accidents alone account for more than 50 percent of the SCI cases. Other causes include sporting accidents, serious falls either at work or at home, wounds, and diseases of the spine such as spina bifida.
The estimated annual global incidence of spinal cord injury is 15 to 40 cases per million. In North America, approximately more than a million individuals live with a disability as a result of spinal cord injury and half of those are quadriplegic, with the paralysis impacting all four limbs to some extent. For those individuals, the lifetime cost of managing their condition and other injury-related expenses is estimated to be between $2 million and $3 million and can reach up to $25 million.
Laceration, contusion, compression, and concussion are hallmarks of the primary injury caused by the initial physical and/or mechanical trauma to the spinal cord. Subsequently, secondary injury giving rise to ischemia, microvascular damage, glutamatergic excitotoxicity, oxidative stress, and inflammation set in further damages to the nerves, leading to formation of a glial scar and paralysis below the site of lesion. Though complete transection of the spinal cord is rare, residual connections usually persist after injury, indicating potential for recovery. Considering the gravity of the medical condition, spinal cord injury has been the main focus of advanced medical research for the past few years and continuous efforts have been made to establish new synapses and provide an appropriate growing environment to already injured parts of the spinal cord.
In recent years, the exciting discovery of neural stem cells derived from adults or embryos has shown great promise as a potential source of neural cells for regenerative therapies. Scientists and researchers around the world are involved in continuing experiments to develop culture systems and drugs that can direct stem cell differentiation in animal models of spinal cord injury.
Stem cell transplantation for SCI has been at the forefront for quite some time now, with animal and in vitro studies providing a solid platform to enable well-designed human studies. Based on the results of past successful preclinical studies, olfactory ensheathing cells seem to be the most promising, whereas bone marrow stromal cells (BMSC) also seem to be strong promising candidates for an adjunctive role.
In clinical trials on stem cell transplantation in spinal cord injury involving animal models, a conclusive meta-analysis and systemic review was done by a team of authors from Australia and the United Kingdom in which they included the data from controlled in vivo studies testing the efficacy of stem cells as a treatment in animal models of traumatic spinal cord injury. In this meta-analysis of 156 publications, the outcomes were reported and compared on a scale of effect size (percentage improvement in motor score and sensory score).
According to this systemic review and meta-analysis, overall allogeneic stem cell treatment in spinal cord injury in animals appears to improve motor function by 27.2 percent and sensory function by 26.3 percent, depending on stem cell dose, its derivation (adult or embryonic), manipulation in culture (genetic, antibiotic, growth factor), number of passages in culture, method of stem cell selection prior to implantation, route of administration, frequency of administration, the presence or absence of a supporting scaffold, time of assessment, anesthetic used, and temperature regulation during surgery.
An injury to the spinal cord can disrupt the cord’s normal motor, sensory, or autonomic function and can be either temporary or permanent. Most often traumatic, spinal cord injuries can include the cervical (neck), thoracic (arms or hands) and/or
